Neuraxis (NRXS) stock
NRXS · Neuraxis Inc. · AMEX
- Market cap
- $63.9M
- Shares out
- 14.2M
What is the latest news on NRXS stock?
SCHEDULE 13D/A - Neuraxis, INC (0001933567) (Subject)
All NRXS newsWhen does Neuraxis report earnings?
Neuraxis last reported on Nov 9, 2026, the date it announced on Oct 27, 2026. Before that it reported on Aug 11, 2026 and May 12, 2026. On that schedule the next report would come around early February 2027, with the date usually announced about 1 week ahead.
NRXS earnings historyWho owns the most NRXS stock?
AIGH Capital Management LLC was the largest reported holder of NRXS at the end of Q2 2026, with 519,938 shares worth $3.8 million. Next came Rosalind Advisors, Inc. ($3.0 million) and Vanguard Capital Management LLC ($2.5 million). In all, 32 institutions reported $19.2 million of NRXS in their 13F filings.
All NRXS fund holdersAre insiders buying or selling NRXS?
No NRXS insider has reported a purchase or sale in the last 90 days. The last trade on file: Timothy Robert Henrichs bought $15K, reported on Apr 3, 2026.
NRXS insider tradesFinancial highlights
Full financials- Revenue, TTM
- $6.53M
- Revenue growth
- +94.3%
- Net income, TTM
- -$12.10M
- Net margin
- -185.2%
- Cash
- $4.48M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
Latest news
25 items- 13D/GAmendment: SEC Form SCHEDULE 13D/A filed by Neuraxis Inc.SCHEDULE 13D/A - Neuraxis, INC (0001933567) (Subject)
- 13D/GAmendment: SEC Form SCHEDULE 13G/A filed by Neuraxis Inc.SCHEDULE 13G/A - Neuraxis, INC (0001933567) (Subject)
- PRNeurAxis Reports Record Third Quarter 2026 Financial Results Driven by 150% Year Over Year Revenue GrowthCARMEL, Ind., Nov. 09, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the third quarter period ended September 30, 2026. 3Q26 Financial Highlights Revenues increased significantly, 150% year over year to $2.0 million.Unit deliveries increased 92%, benefitting from the Category I CPT code effective January 1, 2026, substantially increasing payer coverage.Expanded gross margin by 330 basis points as significantly more devices were sold at full reimbursement price reflective of the Category I C
- SECSEC Form 10-Q filed by Neuraxis Inc.10-Q - Neuraxis, INC (0001933567) (Filer)
- PRNeurAxis to Host Third Quarter 2026 Results and Business Update Call on Monday, November 9, 2026CARMEL, Ind., Oct. 27, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its third quarter period ended September 30, 2026, on Monday, November 9, 2026, before market open. The Company has scheduled a conference call for the same day, Monday, November 9, 2026, at 9:00 am ET to review the results. Conference Call Details Date and Time: Monday, November 9, 2026, at 9:00am ET Toll Free: 1-833-862-0272 (U.S. and Canada toll-free) International: 1-412-634-5915Webcast: https:
- PRNeurAxis Announces Medical Policy Coverage Milestone, Expanding Access to 26 Million Additional Covered LivesCARMEL, Ind., Oct. 15, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis" or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced significant new medical policy coverage from a major national health insurer for Percutaneous Electrical Nerve Field Stimulation ("PENFS"). The coverage spans multiple states and represents approximately 26 million medical plan members. NeurAxis’ proprietary PENFS technology, IB-Stim, is FDA-cleared for the treatment of functional abdominal pain associated with irritable bowel syndrome (IBS) and Functional Dyspepsia (FD) including assoc
- SECSEC Form 8-K filed by Neuraxis Inc.8-K - Neuraxis, INC (0001933567) (Filer)
- INSIDERChief Executive Officer Carrico Brian Allen bought $1,297 worth of shares (268 units at $4.84) (SEC Form 4)4 - Neuraxis, INC (0001933567) (Issuer)
- INSIDERCRO, CCO, CPO Carrico Thomas Joeseph bought $1,588 worth of shares (328 units at $4.84) (SEC Form 4)4 - Neuraxis, INC (0001933567) (Issuer)
- INSIDERChief Financial Officer Henrichs Timothy Robert bought $9,375 worth of shares (1,937 units at $4.84) (SEC Form 4)4 - Neuraxis, INC (0001933567) (Issuer)
- INSIDERSEC Form 3 filed by new insider Blanchard Craig Thomas3 - Neuraxis, INC (0001933567) (Issuer)
- PRNeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial OfficerCARMEL, Ind., Sept. 29, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis" or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced the appointment of Craig Blanchard as Chief Commercial Officer. In this role, Mr. Blanchard will oversee the Company’s commercial functions, including sales and marketing. The appointment of Mr. Blanchard as Chief Commercial Officer represents a strategic investment in the significant growth opportunity NeurAxis sees ahead. With the Company expecting to expand its commercial organization alongside a substantial increase in covered live
- PRNeurAxis Announces Medical Coverage Policy Milestone, Expanding Access to Over 18 million additional Covered LivesCARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis" or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced significant new medical policy coverage from a major national health insurer for Percutaneous Electrical Nerve Field Stimulation ("PENFS"). The coverage spans multiple states and represents approximately 18 million health plan members. NeurAxis’ proprietary PENFS technology, IB-Stim, is FDA-cleared for the treatment of functional abdominal pain associated with irritable bowel syndrome (IBS) and Functional Dyspepsia (FD) including assoc
- PRNeurAxis to Participate in the Lytham Partners Fall 2026 Investor ConferenceCARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2026 Investor Conference, taking place virtually on September 29-30, 2026. Company Webcast The webcast presentation will take place at 11:45 a.m. ET on Tuesday, September 29, 2026. The webcast can be accessed by visiting the conference website at https://lythampartners.com/fall2026/ or directly at https://app.webinar.net/lJ5aBmzWwkZ. Th
- NEWSiAccess Alpha Virtual Best Ideas Fall Investment Conference, September 15-16, 2026RALEIGH, NC / ACCESS Newswire / September 8, 2026 / iAccess Alpha today announced that it will host its Virtual Best Ideas Fall Investment Conference on September 15-16, 2026, bringing together small and microcap public companies and investors for two days of company presentations and 1x1 meetings. The conference will begin on Tuesday, September 15, 2026, with a series of live-streamed company presentations. The second day, Wednesday, September 16, 2026, will be dedicated to 1x1 meetings between presenting companies and pre-qualified investors.How to AttendInvestors and industry professionals may register to view presentations and request 1x1 meetings by visiting the official event website:
- INSIDERCMO, SVP Science & Tech Miranda Adrian was granted 199,106 shares (SEC Form 4) to satisfy tax liability4 - Neuraxis, INC (0001933567) (Issuer)
- INSIDERCRO, CCO, CPO Carrico Thomas Joeseph was granted 193,678 shares, increasing direct ownership by 3,418% to 199,345 units (SEC Form 4) (tax liability)4 - Neuraxis, INC (0001933567) (Issuer)
- INSIDERChief Executive Officer Carrico Brian Allen was granted 199,188 shares, increasing direct ownership by 708% to 227,336 units (SEC Form 4) to satisfy withholding obligation4 - Neuraxis, INC (0001933567) (Issuer)
- SECNeuraxis Inc. filed SEC Form 8-K: Leadership Update, Other Events8-K - Neuraxis, INC (0001933567) (Filer)
- INSIDERDirector Watkins Bradley Mitchell was granted 26,073 shares, increasing direct ownership by 56% to 72,408 units (SEC Form 4)4 - Neuraxis, INC (0001933567) (Issuer)
- INSIDERSEC Form 4 filed by CMO, SVP Science & Tech Miranda Adrian4 - Neuraxis, INC (0001933567) (Issuer)
- INSIDERDirector Keyser Jane Elizabeth was granted 26,073 shares, increasing direct ownership by 56% to 72,408 units (SEC Form 4)4 - Neuraxis, INC (0001933567) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Henrichs Timothy Robert4 - Neuraxis, INC (0001933567) (Issuer)
- INSIDERDirector Ferge Kristin A was granted 31,134 shares, increasing direct ownership by 87% to 67,072 units (SEC Form 4)4 - Neuraxis, INC (0001933567) (Issuer)
- INSIDERSEC Form 4 filed by CRO, CCO, CPO Carrico Thomas Joeseph4 - Neuraxis, INC (0001933567) (Issuer)
NRXS rankings
- Insider7(39%)
- Other3(17%)
- Leadership2(11%)
- SEC Filings2(11%)
- Earnings2(11%)
- 13D/G2(11%)
Neuraxis Inc. (NRXS) is a Biotechnology: Electromedical & Electrotherapeutic Apparatus company listed on AMEX. In the last 30 days Quantisnow tracked 5 wire items for NRXS, including 2 earnings updates, 2 13D/G filings and 1 SEC filing. The most recent was published Nov 16, 2026.
NRXS FAQ
8 questionsWhat is NRXS revenue?
Neuraxis Inc. (NRXS) reported $6.53M of revenue for the twelve months ended Sep 30, 2026. That is up 94.3% from the year before. Revenue for fiscal 2025 was $3.57M.Is NRXS profitable?
No. Neuraxis Inc. reported a net loss of $12.10M for the twelve months ended Sep 30, 2026.How much cash and debt does NRXS have?
Neuraxis Inc. reported $4.48M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does NRXS stock trade?
Neuraxis Inc. (NRXS) is listed on AMEX.What sector and industry is NRXS in?
Neuraxis Inc. operates in the Health Care sector, Biotechnology: Electromedical & Electrotherapeutic Apparatus industry.When did Neuraxis Inc. go public?
Neuraxis Inc. (NRXS) completed its IPO in 2023.What companies are similar to NRXS?
Notable peers in the same industry include ITGR (Integer Holdings Corporation), MDT (Medtronic plc.), INMD (InMode Ltd.), AXGN (Axogen Inc.), TMDX (TransMedics Group Inc.). Compare NRXS side-by-side with any of them on Quantisnow.How can I track NRXS on Quantisnow?
Quantisnow aggregates Neuraxis Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NRXS to receive live email and push alerts on every new disclosure.
Is something on this page wrong, or out of date? Request a change